This exploratory, first-in-man, phase 0 study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland in healthy normal subjects. The researchers believe that \[18F\]FNP-59 would greatly improve the imaging characteristics, by providing a PET imaging cholesterol analogue with significantly improved radiation dosimetry.
Participants without any known adrenal pathology as normal controls for radiation dosimetry purposes
Pregnancy
Unable to do imaging
Body weight greater than 400 lbs (181 Kg)
Prisoners are not eligible
Single group
FNP-59
DrugFNP-59, a radiotracer, is administered for PET/CT scans.
Uptake for [18F]FNP-59 in the adrenal glands using the standardized uptake value (SUV) based on gland segmentation
SUV will be reported. Both maximal and average SUVs will be calculated
Click on the lead sponsor to view all of their trials.
Benjamin Viglianti
Lead sponsor
University of Michigan
Sponsor institution
